Contents
  1. Remdesivir and FIP: Treatment outcomes in feline infectious peritonitis (FIP)
  2. Introduction – Remdesivir and FIP
  3. Overview of FIP and its treatment – Remdesivir and FIP
  4. Study results on the effectiveness of treatment – Remdesivir and FIP
  5. Practical application and dosage – Remdesivir and FIP
  6. Key findings for clinical practice – Remdesivir and FIP
  7. Explanation of GC-376 and GS-441524 with brand names
  8. GC-376
  9. GS-441524
  10. Relationship between GS-441524 and Remdesivir and FIP
  11. GS-441524: The basis
  12. Remdesivir: The big brother
  13. Transition from Remdesivir to GS-441524
  14. Frequently Asked Questions (FAQ) about the treatment of FIP with GS-441524 and Remdesivir
  15. Are GS-441524 and Remdesivir approved in Germany for the treatment of FIP in cats?
  16. Introduction – Remdesivir and FIP
  17. Remdesivir and FIP: Mechanism of action
  18. Studies and clinical experience – Remdesivir and FIP
  19. Treatment protocols – Remdesivir and FIP
  20. Challenges and legal aspects – Remdesivir and FIP
  21. Side effects and risks – Remdesivir and FIP
  22. Success stories – Remdesivir and FIP
  23. Future prospects – Remdesivir and FIP
  24. Conclusion – Remdesivir and FIP

Remdesivir and FIP: Treatment outcomes in feline infectious peritonitis (FIP)

Introduction – Remdesivir and FIP

The Feline Infectious Peritonitis (FIP) For a long time, this disease was considered fatal in cats. However, the discovery of the drugs GC-376 and GS-441524 has significantly improved the prognosis for affected cats. This article presents the latest findings on the effectiveness of these treatment options and their practical application.

Remdesivir and FIP
Remdesivir and FIP 2

Overview of FIP and its treatment – Remdesivir and FIP

FIP is a viral disease caused by the feline coronavirus. The disease occurs in two main forms: the wet form, characterized by abdominal or thoracic effusions, and the dry form, in which granulomatous changes occur in various organs. Until recently, FIP was fatal in almost all cases due to the lack of effective treatment.

Discovery of GC-376 and GS-441524

GC-376 and GS-441524 are antiviral drugs that have proven effective against FIP. GC-376 inhibits the viral protease, thus preventing viral replication. GS-441524, a nucleoside analogue, works by being incorporated into the viral RNA and stopping its replication.

Study results on the effectiveness of treatment – Remdesivir and FIP

A recent study investigated the treatment of 28 cats with FIP using remdesivir (a prodrug of GS-441524) and its oral form. Treatment lasted at least 84 days and involved intravenous administration of remdesivir (10 mg/kg daily for 4 days, followed by 6 mg/kg subcutaneously daily). Cats that had difficulty with the injections subsequently received oral GS-441524 tablets.

Treatment outcomes and survival rate – Remdesivir and FIP

The study found that 861 of the cats survived after six months. The survival rate increased to 961 when cats that died within the first 48 hours were excluded. The relapse rate within six months was 301 in the low-dose remdesivir group, while there were no relapses in the high-dose group or the group that switched to oral GS-441524.

Practical application and dosage – Remdesivir and FIP

The optimal dosage and duration of treatment have not yet been definitively established, but may range from 10 to 15 mg/kg daily for 84 days or longer. Both oral and injectable forms of the medication have proven effective.

graph TD; A[Diagnosis FIP] –> B[Intravenous administration of remdesivir] B –> C[Transition to subcutaneous administration of remdesivir] C –> D[Oral administration of GS-441524] D –> E[Success criteria: Reduction of fever and effusion, weight gain] E –> F[Survival rate after 6 months]

Key findings for clinical practice – Remdesivir and FIP

  1. High efficacyGC-376 and GS-441524 can achieve a cure rate of over 85% in cats with FIP.
  2. Rapid clinical responseThe clinical and laboratory response is often rapid and a good predictor of long-term success.
  3. Various dosage formsBoth the oral and injectable forms of the medication are effective.
  4. Ongoing researchThe ideal dosage, route of administration, combination or concomitant therapies, and transition plans have not yet been fully determined and remain the subject of active research.
  5. Legal and ethical considerationsIn many countries, these medications are difficult to obtain due to legal uncertainties. The legal and ethical implications should be discussed with animal owners.

The treatment of FIP with GC-376 and GS-441524 represents a significant advance in veterinary medicine. These medications offer affected cats a real chance of recovery and considerably improve their quality of life. Ongoing research will help to further optimize treatment protocols and thus further increase the survival chances for cats with FIP.

Explanation of GC-376 and GS-441524 with brand names

GC-376

Description and mode of action

GC-376 is a protease inhibitor specifically designed to inhibit the replication of feline coronavirus (FCoV), the cause of FIP. By inhibiting the main viral protease, GC-376 prevents viral replication, thereby reducing the viral load in the cat's body.

Brand name

Under the brand name Xraphconn GC-376 is well-known. Xraphconn has made a name for itself in the veterinary community due to its efficacy and good tolerability.

GS-441524

Description and mode of action

GS-441524 is a nucleoside analogue that works by being incorporated into viral RNA and stopping viral replication. This drug is a prodrug of remdesivir, which was originally developed to treat Ebola and later COVID-19 in humans.

Brand name

GS-441524 is sold under the brand name Mutian Mutian is well-known and has established itself as an effective and well-tolerated treatment option for cats with FIP. It offers a flexible treatment option in both injectable and oral forms.

Relationship between GS-441524 and Remdesivir and FIP

In the treatment of feline infectious peritonitis (FIP), the antiviral drugs GS-441524 and remdesivir have proven particularly effective. Both drugs are closely related and belong to the same pharmacological family. This article explains the relationship between GS-441524 and remdesivir and their significance for the treatment of FIP in cats.

GS-441524: The basis

Mode of action

GS-441524 is a nucleoside analogue that is incorporated into viral RNA and inhibits viral replication. It is the active metabolite of remdesivir and acts directly against feline coronavirus (FCoV), which causes FIP. In clinical trials, GS-441524 has demonstrated high efficacy and good tolerability in the treatment of FIP.

Availability and usage

GS-441524 is sold under the brand name Mutian It is well-known and frequently used in veterinary medicine. It is available in injectable and oral forms, allowing for flexibility in treatment.

Remdesivir: The big brother

Mode of action

Remdesivir is a prodrug that is converted in the body to GS-441524. It was originally developed to treat Ebola and later used to treat COVID-19 in humans. Remdesivir inhibits the virus's RNA polymerase, thereby effectively preventing viral replication.

Use in cats

In the treatment of FIP in cats, remdesivir is administered intravenously and shows similar efficacy to GS-441524. Intravenous administration of remdesivir can be particularly useful when rapid and intensive treatment is required.

Transition from Remdesivir to GS-441524

Treatment protocol

In many cases, FIP treatment begins with an initial dose of remdesivir. Treatment often starts with intravenous administration of remdesivir to achieve a rapid reduction in viral load. After this initial phase, treatment is frequently switched to oral administration of GS-441524 to continue therapy and suppress viral replication in the long term.

Frequently Asked Questions (FAQ) about the treatment of FIP with GS-441524 and Remdesivir

What is Feline Infectious Peritonitis (FIP) and how is it diagnosed?

Feline infectious peritonitis (FIP) is a severe, often fatal disease in cats caused by the feline coronavirus (FCoV). There are two main forms of FIP: the wet form, characterized by fluid accumulation in the abdomen or chest, and the dry form, in which granulomatous inflammation occurs in various organs. Both forms lead to serious health problems and are usually fatal without treatment.
Diagnosing FIP is complex and requires a combination of clinical signs, laboratory findings, and specific tests. Diagnostic methods include:
Clinical signsThese include fever, weight loss, loss of appetite, fatigue, jaundice, and changes in the eyes.
Laboratory findingsBlood tests may show elevated globulin levels, decreased albumin-globulin ratios, and signs of inflammation.
Imaging proceduresUltrasound examinations can reveal fluid accumulations or organ changes.
Special testsPCR (polymerase chain reaction) and immunocytochemistry are important to directly detect the virus and confirm the diagnosis.
A definitive diagnosis is often made through a combination of these methods, as no single method is absolutely certain.

How do GS-441524 and Remdesivir work in the treatment of FIP?

GS-441524 and Remdesivir are antiviral drugs that have proven effective in treating FIP. Both drugs work by inhibiting viral replication, but they have different mechanisms and methods of administration.
GS-441524This drug is a nucleoside analogue and the active metabolite of remdesivir. It is directly incorporated into viral RNA, thereby stopping viral replication. GS-441524 is available under the brand name [brand name missing in original text]. Mutian It is well-known and can be administered both orally and by injection. Treatment usually lasts for at least 84 days.
RemdesivirRemdesivir is a prodrug that is metabolized in the body to GS-441524. It was originally developed to treat Ebola and later to treat COVID-19 in humans. In veterinary medicine, remdesivir is administered intravenously and can be particularly useful in acute cases of FIP. The initial treatment with remdesivir can then be supplemented by oral administration of GS-441524.
Both medications have been shown to significantly improve the survival chances of cats with FIP and are often used in combination to achieve the best therapeutic effect.

What side effects can occur during treatment with GS-441524 and Remdesivir for FIP?

As with all medications, side effects can occur during treatment with GS-441524 and Remdesivir. However, these are usually rare and mostly mild. Known side effects include:
Local reactions at the injection siteThese include swelling, redness, and pain that may occur with subcutaneous administration. These symptoms are usually temporary and subside after a few days.
Digestive problemsSome cats may develop diarrhea or vomiting during oral treatment with GS-441524. These symptoms are usually mild and temporary.
Liver and kidney valuesIn some cats, liver and kidney values may change during treatment. Regular blood tests are important to monitor these parameters and adjust the dosage if necessary.
Loss of appetite and fatigueSome cats may temporarily eat less and feel more tired than usual during treatment. These symptoms should be closely monitored to ensure they do not indicate a more serious side effect.
It is important that pet owners work closely with their veterinarian to monitor their cat's health during treatment and to take immediate action if any side effects occur.

How long does treatment for FIP with these medications take and when are the first improvements visible?

Treatment of FIP with GS-441524 and Remdesivir is usually lengthy and can last at least 84 days. The exact duration of treatment depends on the severity of the disease and the cat's response to therapy.
Initial phase of treatmentIn the first days to weeks of treatment, intravenous injections of Remdesivir are often administered, especially in severe cases or cats that need a quick response.
Transition phaseAfter initial stabilization, treatment is often switched to oral administration of GS-441524. This phase usually lasts several weeks.
long-term treatmentTo ensure the virus is completely under control, treatment often continues for several months. Regular veterinary check-ups and blood tests are necessary to adjust the therapy and monitor the cat's health.
Initial improvements may be visible within the first few days of treatment. These include a reduction in fever, improved appetite, and increased activity. In many cases, the cat regains weight and shows a significant improvement in its overall condition within the first two weeks.

Where can I obtain GS-441524 and Remdesivir to treat my cat, and what are the costs?

GS-441524 and Remdesivir are specialized medications and are not readily available in all countries. Here is some important information regarding procurement and costs:
procurementThe availability of these medications can vary from country to country. In some countries, they are only available through specific veterinary prescriptions, while in others they may not be legally available. It is important to consult with an experienced veterinarian who is familiar with the treatment of FIP and has access to these medications.
CostsThe cost of treating FIP with GS-441524 and Remdesivir can be substantial. A complete course of treatment can cost several thousand euros, depending on the dosage and duration. These costs include the medication itself, veterinary services, and regular blood tests to monitor the treatment.
Experienced veterinarianIt is advisable to consult a veterinarian experienced in treating FIP. Such veterinarians often have better sources for obtaining medication and can offer sound advice.
In summary, treating FIP with GS-441524 and Remdesivir is a significant investment, but one that can substantially improve the survival chances and quality of life of affected cats. Close collaboration with a specialized veterinarian is key to the success of this therapy.






Are GS-441524 and Remdesivir approved in Germany for the treatment of FIP in cats?





GS-441524





GS-441524 is not currently officially approved in Germany for the treatment of FIP in cats. However, it is frequently prescribed by veterinarians via so-called "off-label use." This means that veterinarians can use the drug to save cats' lives despite the lack of official approval. In some cases, a special import permit can be applied for to import GS-441524 from abroad.American Animal Hospital Association)​​ (FIP Treatment Guide)​.





Remdesivir





Remdesivir is approved in Germany as a medication for the treatment of COVID-19 in humans. It is also used "off-label" for the treatment of FIP in cats. Remdesivir can be administered intravenously, especially in acute cases or if the cat does not tolerate oral medication. However, there is no specific veterinary approval for remdesivir for the treatment of FIP, which is why veterinarians need informed consent from pet owners before prescribing it.Epicur Pharma®)​​ (FIP Treatment Guide)​.





Practical steps for cat owners – Remdesivir and FIP





    

  1. Consultation with a specialized veterinarianConsult a veterinarian experienced in treating FIP. These specialists can provide better information on the latest developments and alternative procurement options.
    2. 




  2. Import permitConsider applying for an import permit for GS-441524 with your veterinarian to legally obtain the medication from abroad.
    3. 




  3. Off-label use: Consult your veterinarian about the possibilities and risks of the "off-label" use of Remdesivir and GS-441524.
    4. 






While GS-441524 and Remdesivir are not officially approved for the treatment of FIP in cats in Germany, there are still ways for affected cats to access these life-saving medications. Close collaboration with experienced veterinarians and a careful consideration of the legal and health aspects are crucial. With sound information and targeted measures, cat owners can do the best for the health of their beloved animals.BOVA GLOBAL)​​ (American Animal Hospital Association)​​ (FIP Treatment Guide)​.





„"Off-label use" means that a drug is used outside of its officially approved indications. This means the drug is used for a different condition, at a different dosage, or for a different patient group than specified in the approval by the relevant health authority (such as the EMA in Europe or the FDA in the USA).





Examples of off-label use – Remdesivir and FIP





    

  1. Other illnessA drug originally developed to treat one disease is used to treat another. For example, Remdesivir, which was originally approved for Ebola and later for COVID-19, is used "off-label" to treat FIP in cats.
    2. 




  2. Other dosageA drug is used in a different dosage or form of administration than officially approved. For example, a drug that is only approved in tablet form could be administered as an injection.
    3. 




  3. Other patient group: A drug that is only approved for adults is used on children, or a drug that is approved for humans is used on animals.
    4. 






Legal and ethical aspects – Remdesivir and FIP





Off-label use is legal, but it presents several legal and ethical challenges. Physicians and veterinarians must take responsibility for its use and ensure that patients or pet owners are fully informed about the potential risks and benefits. Informed consent is crucial.





Advantages and risks





Advantages:





    

  • flexibilityDoctors and veterinarians can respond to new findings and the individual needs of their patients.
    • 




  • InnovationsOff-label use allows for the discovery and testing of new therapeutic approaches.
    • 






Risks:





    

  • Lack of dataThere may be less scientific data and clinical studies to support off-label use.
    • 




  • Legal liabilityIn case of side effects or failures, legal consequences could arise.
    • 






Off-label use is an important part of medical practice, allowing for a flexible and innovative approach to individual health needs. However, it requires careful consideration and comprehensive education of patients or pet owners.





Summary of the study on Remdesivir and FIP





Introduction – Remdesivir and FIP





Feline infectious peritonitis (FIP) is a severe and often fatal disease in cats caused by the feline coronavirus (FCoV). Treatment options were limited for a long time, but in recent years remdesivir has emerged as a promising option. This summary highlights the importance of remdesivir and FIP.





Remdesivir and FIP: Mechanism of action





Remdesivir is an antiviral drug originally developed to treat Ebola and later used to treat COVID-19 in humans. It works by inhibiting the virus's RNA polymerase, thereby effectively stopping viral replication. Remdesivir has proven effective in treating FIP by inhibiting the replication of the feline coronavirus.





Studies and clinical experience – Remdesivir and FIP





Several studies have shown that remdesivir is highly effective in treating FIP. In clinical trials, cats treated with remdesivir showed significant improvements in their health. Remdesivir and FIP have therefore become an important topic in veterinary medicine.





Treatment protocols – Remdesivir and FIP





Treatment of FIP with remdesivir typically lasts at least 84 days. Initial therapy often begins with intravenous administration, particularly in acute cases or if the cat does not tolerate oral medication. Once the cat is stabilized, treatment can be switched to oral administration of GS-441524, a related drug. This protocol has proven successful in many cases and demonstrates the importance of remdesivir and FIP in modern veterinary medicine.





Challenges and legal aspects – Remdesivir and FIP





Although remdesivir shows promising results in the treatment of FIP, some challenges remain. In many countries, including Germany, remdesivir is not officially approved for the treatment of FIP in cats. Its use is "off-label," meaning that veterinarians use the drug despite the lack of specific approval. This requires informed consent from pet owners and close monitoring of the treatment. The legal and ethical implications of remdesivir and FIP are therefore important considerations for veterinarians and cat owners.





Side effects and risks – Remdesivir and FIP





As with all medications, side effects can occur when treating FIP with remdesivir. The most common include local reactions at the injection site, digestive problems, and changes in liver and kidney function. It is important to monitor these potential side effects and adjust the treatment accordingly. Remdesivir and FIP therefore require careful and responsible use.





Success stories – Remdesivir and FIP





Many cat owners report impressive successes in treating FIP with Remdesivir. Cats previously considered incurable have made full recoveries and regained normal lives. These success stories underscore the importance of Remdesivir and FIP in modern veterinary medicine.





Future prospects – Remdesivir and FIP





Research on remdesivir and FIP is ongoing. Scientists are continuously working to develop optimal dosages and treatment protocols. Future studies will help to further improve efficacy and make treatment safer. Remdesivir and FIP therefore remain a dynamic and evolving field of research.





Conclusion – Remdesivir and FIP





Remdesivir and FIP have revolutionized veterinary medicine, offering new hope to affected cats. Despite legal and practical challenges, the treatment shows promising results and significantly improves the survival chances and quality of life of affected cats. Close collaboration between veterinarians and cat owners, as well as ongoing research, are crucial to further advancing these advances.





Overall, it is clear that Remdesivir and FIP represent a significant and forward-looking topic in veterinary medicine. The positive developments and numerous success stories give cause for hope and motivate further research and optimization of this treatment method.





Further information on the current study: https://www.cliniciansbrief.com/article/feline-infectious-peritonitis-treatment-outcomes?utm_medium=email&utm_source=newsletter&utm_campaign=Online+240708&oly_enc_id=4679H0135945H8Y





Related posts:
    

  1. Chronic diseases in animals
    2. 

  2. Prussic acid poisoning in animals
    3. 

  3. Giardia in cats
    4. 

  4. Mucopolysaccharidosis in cats
    5. 





		
		
			




						
				



			

			
		
	



	

	

		
		
		
	





	
 
	


		
			



		
		
		

	





					


		Scroll to Top